Form 8-K · Current report
NXP Semiconductors 8-K, filed Oct 27, 2026
- Filed
- CIK
- 0001413447
- Accession no.
- 0001413447-26-000057
Summary
NXP Semiconductors reported third-quarter 2026 revenue of $3.79 billion, up 19% year over year, and announced a $5 billion increase to its share repurchase authorization. The company guided fourth-quarter revenue to $3.75–$3.95 billion.
Key points
- Third-quarter GAAP diluted net income per share was $3.48; non-GAAP diluted net income per share was $4.20.
- Cash flow from operations was $1.26 billion, with non-GAAP free cash flow of $1.21 billion, or 31.9% of revenue.
- NXP said its Trimension ultra-wideband ranging and radar solutions will be deployed by BMW Group across its fleet starting with selected 2026 vehicle programs.
- VSMC, a joint venture between Vanguard International Semiconductor and NXP, marked the grand opening of its first 300mm fab in Singapore.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02 Results of Operations and Financial Condition. On October 27, 2026, NXP Semiconductors N.V. ("NXP") issued a press release regarding NXP’s financial results for its third quarter 2026. A copy of the press release is attached as Exhibit 99.1. The information contained in this Item 2.02, including the attached exhibit, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.